… stroke and systemic embolism for patients on OACs compared with patients with normal renal
function. However, current stroke … higher RR of stroke or systemic embolism. The indication …

… patients had a higher rate of stroke and embolism irrespective of which treatment they received.
… The reduction in the primary outcome of stroke or systemic embolism was consistent in …

… to prevent ischaemic stroke and systemic embolism, those … K antagonism for prevention of
stroke and Embolism Trial in … warfarin for prevention of all stroke and systemic embolism in 14 …

… reduces the risk of stroke but also reduces the risk of systemic embolism. Warfarin is better
than placebo and antiplatelet treatment in prevention of systemic embolism in these patients. …

… atrial fibrillation who were at risk of stroke or systemic embolism were enrolled to receive either
… the risk of stroke or systemic embolism without significantly increasing the safety concern. …

… in AF patients is associated with higher mortality and costlier hospital stays than stroke in …
systemic embolism (SE) which may result in major damage to limbs and organs (eg embolism …

… The ARISTOTLE trial reported the composite event rate for stroke or systemic embolism in
the SOT population but not the individual event rate for IS and systemic embolism, respectively…

… We assessed the risk of early events (death, stroke/systemic embolism, and major bleeding)
over 12 months and their relation to the time after diagnosis of atrial fibrillation in 52 014 …

Objective To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant,
versus warfarin and other alternatives for the prevention of stroke and systemic embolism in …

… in preventing stroke and systemic embolism events. Importantly, these products offer similar
benefits in reducing or maintaining the safety, compared with VKA treatment. For example, a …